• Explore /
  • Poster
  • / Stage 1 results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas (NCT03355976).

Stage 1 results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas (NCT03355976).

Abstract Video & Slides Poster

Authors

Don S. Dizon

Don S. Dizon

Lifespan Cancer Institute and Brown University, Providence, RI

Don S. Dizon , Katina Robison , Shannon Diane MacLaughlan David , Jason T Machan , Matthew James Hadfield , Eric I Marks , Rani Chudasama , Tarra Evans , Mary Lorraine Lopresti , Emma Safran , Michaela Kastura , Faith Hassinger , Ashlee Sturtevant , Roxanne Wood , Alexi A. Wright , Rochelle Strenger , Ursula A. Matulonis , Christina Bandera , Susana M. Campos , Michael J. Birrer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Other Gynecologic Cancer

Clinical Trial Registration Number

NCT03355976

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 5598)

DOI

10.1200/JCO.2022.40.16_suppl.5598

Abstract #

5598

Poster Bd #

474

Abstract Disclosures

Similar Posters

First Author: Michael B. Atkins

First Author: Alona Zer

First Author: Elisa A. Rozeman

First Author: Charlee Nardin